Is Anti-Müllerian Hormone a Marker of Ovarian Reserve in Young Breast Cancer Patients Receiving a GnRH Analog during Chemotherapy?
Breast Care · 2022 · 17 (1) · 10-15
DOI: 10.1159/000514445 ↗Kurz gefasst
Fachartikel in der Zeitschrift Breast Care, online erschienen am 04.03.2021. Verfasst von Rosalba Torrisi und 7 weiteren Autor:innen. Beteiligte Einrichtung: IRCCS Humanitas Research Hospital Medical Oncology Unit, Rozzano, Italy. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Introduction
Anti-Müllerian hormone (AMH) is the most reliable biomarker of ovarian reserve; however, its role in predicting ovarian recovery after chemotherapy is unclear. Administration of a GnRH analog (GnRHa) during chemotherapy significantly reduces the ovarian failure rate and increases the pregnancy rate. The available data on the behavior of AMH during concurrent administration of chemotherapy and GnRHa are inconsistent. We investigated whether concurrent administration of triptorelin and adjuvant chemotherapy might reduce the expected drop of AMH.
Methods
Eligible patients were premenopausal women aged <40 years, with a diagnosis of early breast cancer, and candidates to 4–8 cycles of adjuvant chemotherapy. Triptorelin (3.75 mg i.m.) was started before chemotherapy and administered every 4 weeks thereafter. The principal endpoint was the proportion of patients with an AMH percent change ≤50% between 12 months after chemotherapy and basal levels. The secondary endpoint was the proportion of patients achieving postchemotherapy AMH levels above the threshold of 0.2 ng/mL.
Results
Fifty patients were enrolled, 31 of whom had blood samples available at baseline and 1 year after the end of chemotherapy. AMH decreased to nearly undetectable levels after chemotherapy and recovered after 12 months, but they did not exceed 1 tenth of the pretreatment levels. As for the secondary endpoint, 15 of the 31 patients recovered AMH levels above the threshold.
Conclusions
This study did not reach its principal endpoint; however, the rate of 48% of patients who recovered AMH above threshold levels favorably compared with those in studies without concurrent GnRHa, supporting a better recovery of AMH with triptorelin.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- IRCCS Humanitas Research Hospital Medical Oncology Unit, Rozzano, Italy.
- Medical Oncology Unit, Istituto Clinico Mater Domini Humanitas, Castellanza, Italy.
- Medical Oncology Humanitas Centro Catanese di Oncologia, Catania, Italy.
- Breast Unit, University Hospital of Parma, Parma, Italy.
- Laboratory of Clinical Analysis, Humanitas Clinical and Research Center, IRCCS, Rozzano, Italy.
- Department of Biomedical Sciences, Humanitas University, Rozzano, Italy.
Zitieren
APA
Torrisi, R., Basilico, V., Giordano, L., Caruso, M., Musolino, A., Monari, M. N., Carnaghi, C., & Santoro, A. (2022). Is Anti-Müllerian Hormone a Marker of Ovarian Reserve in Young Breast Cancer Patients Receiving a GnRH Analog during Chemotherapy?. Breast Care, 17(1), 10-15. https://doi.org/10.1159/000514445
Vancouver
Torrisi R, Basilico V, Giordano L, Caruso M, Musolino A, Monari MN, et al. Is Anti-Müllerian Hormone a Marker of Ovarian Reserve in Young Breast Cancer Patients Receiving a GnRH Analog during Chemotherapy?. Breast Care. 2022;17(1):10-15. doi:10.1159/000514445
BibTeX
@article{Torrisi2022,
author = {Torrisi, Rosalba and Basilico, Vera and Giordano, Laura and Caruso, Michele and Musolino, Antonino and Monari, Marta Noemi and Carnaghi, Carlo and Santoro, Armando},
title = {Is Anti-Müllerian Hormone a Marker of Ovarian Reserve in Young Breast Cancer Patients Receiving a GnRH Analog during Chemotherapy?},
journal = {Breast Care},
year = {2022},
volume = {17},
number = {1},
pages = {10--15},
doi = {10.1159/000514445}
}
EUVIMED